The G-protein-biased agents PZM21 and TRV130 are partial agonists of μ-opioid receptor-mediated signalling to ion channels

G蛋白偏向性激动剂PZM21和TRV130是μ-阿片受体介导的离子通道信号传导的部分激动剂。

阅读:1

Abstract

BACKGROUND AND PURPOSE: Opioids remain the most efficient medications against severe pain; they act on receptors that couple to heterotrimeric G-proteins in the G(αi/o) family. Opioids exert many of their acute effects through modulating ion channels via G(βγ) subunits. Many of their side effects are attributed to β-arrestin recruitment. Several biased agonists that do not recruit β-arrestins, but activate G-protein-dependent pathways, have recently been developed. While these compounds have been proposed to be full agonists of G-protein signalling in several high throughput pharmacological assays, their effects were not studied on ion channel targets. EXPERIMENTAL APPROACH: Here, we used patch-clamp electrophysiology and Ca(2+) imaging to test the effects of TRV130, PZM21, and herkinorin, three G-protein-biased agonists of μ-opioid receptors, on ion channel targets of G(αi/o) /G(βγ) signalling. We also studied G-protein dissociation using a FRET-based assay. KEY RESULTS: All three biased agonists induced smaller activation of G-protein-coupled inwardly rectifying K(+) channels (K(ir) 3.2) and smaller inhibition of transient receptor potential melastatin (TRPM3) channels than the full μ receptor agonist DAMGO. Co-application of TRV130 or PZM21, but not herkinorin, alleviated the effects of DAMGO on both channels. PZM21 and TRV130 also decreased the effect of morphine on K(ir) 3.2 channels. The Ca(V) 2.2 channel was also inhibited less by PZM21 and TRV130 than by DAMGO. We also found that TRV130, PZM21, and herkinorin were less effective than DAMGO at inducing dissociation of the G(αi) /G(βγ) complex. CONCLUSION AND IMPLICATIONS: TRV130, PZM21, and potentially herkinorin are partial agonists of μ receptors.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。